Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Mr. Lindquist brings decades of leadership experience across pharmaceutical ...
Peer-reviewed manuscript demonstrates the Endocrine Activity Index TM Recurrence Risk (EAI RR) enhances risk stratification beyond Recurrence Score® and is predictive of endocrine therapy benefit ...
HOUSTON, Nov. 4, 2025 /PRNewswire/ -- Delphi Diagnostics announces the upcoming presentation of four scientific abstracts, including one platform presentation highlighting new clinical data supporting ...
HOUSTON, May 19, 2026 /PRNewswire/ -- Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Mr. Lindquist brings decades of ...
The study, which analyzed 659 patient samples from the PACS-01 clinical trial, demonstrates that EAI RR provides meaningful prognostic and endocrine-predictive information beyond the 21-gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results